フルベストラント注射剤の世界市場レポート 2025年

フルベストラント注射剤市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.1％で18億3,000万米ドルに成長します。予測期間の成長は、併用療法へのシフト、バイオシミラーの導入によるアクセシビリティの向上、新興市場での拡大、個別化がん治療の重視の高まり、新規適応症の臨床試験への投資の増加などに起因すると考えられます。この期間に予想される主な動向には、フルベストラント注射剤の進歩、併用療法の開発、皮下投与法の研究、バイオマーカーターゲティングによる個別化医療アプローチの統合などがあります。

乳がんの有病率の上昇は、今後数年間のフルベストラント注射剤市場の成長を促進すると予想されます。乳がんは、乳腺組織における異常細胞の制御不能な増殖を特徴とし、悪性腫瘍の形成につながり、近隣組織への浸潤や身体の他の部位への転移を引き起こす可能性があります。このような有病率の増加は、人口の高齢化が主な原因です。エストロゲンへの曝露が長期化し、遺伝子変異が徐々に蓄積するため、乳がんを発症するリスクは加齢とともに上昇するからです。フルベストラント注射剤は、エストロゲンの腫瘍増殖作用を阻害することで、ホルモン受容体陽性乳がんの治療に重要な役割を果たし、進行型や治療抵抗性の乳がん患者に有効な選択肢を提供し、全体的な治療成績を向上させる。例えば、米国を拠点とする非営利団体Breastcancer.orgは2025年3月、乳がんは新規がん診断の約32％を占め、2025年までに浸潤性乳がんと診断される女性は31万6,950人、非浸潤性乳がんと診断される女性は5万9,080人と推定されると報告しています。その結果、乳がん罹患率の増加がフルベストラント注射剤市場の拡大に大きく寄与しています。

フルベストラント注射剤市場の主要企業は、製品ポートフォリオの拡充と市場でのプレゼンス強化のため、規制当局の承認取得を優先しています。薬事承認とは、製品が安全性、有効性、品質に関する確立された基準に適合していることを確認するために、政府機関から与えられる公式な認可です。例えば、2022年12月、インドの製薬会社Alembic Pharmaceuticalsは、ホルモン受容体陽性乳がんの治療を適応とするジェネリック医薬品フルベストラント注射剤（250mg/5mL）について、米国食品医薬品局（USFDA）から簡略新薬承認申請（ANDA）の承認を取得しました。フルベストラントは筋肉内注射により投与され、通常、医療従事者が所定のスケジュールに従って投与します。フルベストラントは、エストロゲン受容体に結合して分解することにより、エストロゲンがホルモン受容体陽性乳がん細胞の増殖を促進するのを阻害します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のフルベストラント注射剤：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のフルベストラント注射剤市場：成長率分析
• 世界のフルベストラント注射剤市場の実績：規模と成長、2019年～2024年
• 世界のフルベストラント注射剤市場の予測：規模と成長、2024年～2029年、2034年
• 世界のフルベストラント注射剤：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のフルベストラント注射剤市場：タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 先発医薬品
• ジェネリック医薬品
• 世界のフルベストラント注射剤市場：投与量別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 単回投与バイアル
• マルチドーズバイアル
• プレフィルドシリンジ
• 世界のフルベストラント注射剤市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 筋肉内注射
• 皮下注射
• 静脈注射
• 世界のフルベストラント注射剤市場：用途別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 乳がんの治療
• ホルモン受容体陽性転移性乳がん
• その他の用途
• 世界のフルベストラント注射剤市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のフルベストラント注射剤市場、先発医薬品の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• ブランド処方
• 特許取得済み分子
• 病院調達ブランド
• 腫瘍専門医が処方するブランド
• 高コストセグメント
• 世界のフルベストラント注射剤市場、ジェネリック医薬品の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• ブランドジェネリック
• 非ブランドジェネリック
• バイオシミラージェネリック
• 低コストの機関向けジェネリック医薬品
• 入札ベースの供給ジェネリック

第7章 地域別・国別分析

• 世界のフルベストラント注射剤市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界のフルベストラント注射剤市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• フルベストラント注射剤市場：競合情勢
• フルベストラント注射剤市場：企業プロファイル
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis
  • Intas Pharmaceuticals Limited Overview, Products and Services, Strategy and Financial Analysis
  • Sandoz Group AG Overview, Products and Services, Strategy and Financial Analysis
  • Apotex Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Dr. Reddy's Laboratories
• Cadila Pharmaceuticals Ltd.
• Amneal Pharmaceuticals Inc.
• Biocon Ltd.
• Glenmark Pharmaceuticals Ltd.
• Alkem Laboratories Ltd.
• Alembic Pharmaceuticals
• Eskayef Pharmaceuticals Ltd.
• Natco Pharma Ltd.
• Celon Laboratories Ltd.
• Therdose Pharma
• Eugia Pharma
• Formative Pharma
• Halsted Pharma
• Metta Life Sciences

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• フルベストラント注射剤市場2029年：新たな機会を提供する国
• フルベストラント注射剤市場2029年：新たな機会を提供するセグメント
• フルベストラント注射剤市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Fulvestrant injection is a synthetic estrogen receptor antagonist used to treat hormone receptor-positive breast cancer in postmenopausal women. It functions by blocking and degrading estrogen receptors, thereby inhibiting the growth of cancer cells that depend on estrogen. This mechanism helps to slow or stop tumor progression, ultimately improving patient outcomes.

Fulvestrant injections are classified into original drugs and generic drugs. Original drugs refer to the first formulations developed and introduced by pharmaceutical companies. These injections come in various dosage forms, such as single-dose vials, multi-dose vials, and pre-filled syringes, and are administered via intramuscular, subcutaneous, or intravenous routes. They are used for treating breast cancer, hormone receptor-positive metastatic breast cancer, and other related conditions. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.

The fulvestrant injection market research report is one of a series of new reports from The Business Research Company that provides fulvestrant injection market statistics, including fulvestrant injection industry global market size, regional shares, competitors with a fulvestrant injection market share, detailed fulvestrant injection market segments, market trends and opportunities, and any further data you may need to thrive in the fulvestrant injection industry. This fulvestrant injection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The fulvestrant injection market size has grown strongly in recent years. It will grow from $1.24 billion in 2024 to $1.34 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be credited to the rising incidence of breast cancer, greater awareness of hormone receptor-positive breast cancer, the presence of branded fulvestrant products, expansion of oncology treatment infrastructure, and supportive reimbursement policies in developed nations.

The fulvestrant injection market size is expected to see strong growth in the next few years. It will grow to $1.83 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to a shift toward combination therapies, increased accessibility due to the introduction of biosimilars, expansion in emerging markets, a rising emphasis on personalized cancer treatment, and increased investment in clinical trials for new indications. Key trends expected during this period include advancements in fulvestrant injection, the development of combination therapies, investigation into subcutaneous delivery methods, and the integration of personalized medicine approaches through biomarker targeting.

The rising prevalence of breast cancer is anticipated to drive the growth of the fulvestrant injection market in the coming years. Breast cancer is characterized by the uncontrolled proliferation of abnormal cells in breast tissue, leading to the formation of malignant tumors that may invade nearby tissues or metastasize to other parts of the body. This increasing prevalence is largely due to aging populations, as the risk of developing breast cancer rises with age because of prolonged estrogen exposure and the gradual buildup of genetic mutations. Fulvestrant injection plays a crucial role in treating hormone receptor-positive breast cancer by blocking estrogen's effect on tumor growth, offering an effective option for patients with advanced or treatment-resistant forms of the disease and improving overall treatment outcomes. For example, in March 2025, Breastcancer.org, a U.S.-based nonprofit organization, reported that breast cancer represents approximately 32% of all new cancer diagnoses, with an estimated 316,950 women projected to be diagnosed with invasive breast cancer and 59,080 with non-invasive types by 2025. As a result, the growing incidence of breast cancer is contributing significantly to the expansion of the fulvestrant injection market.

Leading companies in the fulvestrant injection market are prioritizing the acquisition of regulatory approvals to broaden their product portfolios and strengthen their market presence. Regulatory approvals are official authorizations granted by government agencies, confirming that a product complies with established standards for safety, efficacy, and quality. For example, in December 2022, Alembic Pharmaceuticals, an India-based pharmaceutical firm, received an Abbreviated New Drug Application (ANDA) approval from the U.S. Food & Drug Administration (USFDA) for its generic Fulvestrant injection (250 mg/5 mL), indicated for the treatment of hormone receptor-positive breast cancer. Fulvestrant is delivered via intramuscular injection, typically administered by a healthcare provider following a prescribed schedule. It functions by binding to and degrading estrogen receptors, thereby preventing estrogen from promoting the growth of hormone receptor-positive breast cancer cells.

In November 2024, Incyclix Bio LLC, a U.S.-based clinical-stage biopharmaceutical company, entered into a partnership with Eli Lilly and Company to advance the development of breast cancer treatments. The collaboration is focused on assessing whether the addition of the CDK2 inhibitor INX-315 to the existing combination of Verzenio (abemaciclib) and fulvestrant can enhance clinical outcomes in patients with HR+/HER2- metastatic breast cancer who have experienced disease progression following prior CDK4/6 inhibitor therapy. Eli Lilly and Company is a pharmaceutical company based in the United States.

Major players in the fulvestrant injection market are AstraZeneca plc, Fresenius Kabi AG, Intas Pharmaceuticals Limited, Sandoz Group AG, Apotex Inc., Dr. Reddy's Laboratories, Cadila Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Biocon Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Alembic Pharmaceuticals, Eskayef Pharmaceuticals Ltd., Natco Pharma Ltd., Celon Laboratories Ltd., Therdose Pharma, Eugia Pharma, Formative Pharma, Halsted Pharma, and Metta Life Sciences.

North America was the largest region in the fulvestrant injection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fulvestrant injection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fulvestrant injection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fulvestrant injection market consists of sales of ready-to-use formulations and depot injections. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fulvestrant Injection Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fulvestrant injection market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fulvestrant injection ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fulvestrant injection market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Original Drugs; Generic Drugs
• 2) By Dosage Formulation: Single-Dose Vials; Multi-Dose Vials; Pre-Filled Syringes
• 3) By Administration Route: Intramuscular Injection; Subcutaneous Injection; Intravenous Injection
• 4) By Application: Breast Cancer Treatment; Hormone Receptor-Positive Metastatic Breast Cancer; Other Applications
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Original Drugs: Branded Formulations; Patented Molecules; Hospital-Procured Brands; Oncologist-Prescribed Brands; High-Cost Segment
• 2) By Generic Drugs: Branded Generics; Non-Branded Generics; Biosimilar Generics; Low-Cost Institutional Generics; Tender-Based Supply Generics
• Companies Mentioned: AstraZeneca plc; Fresenius Kabi AG; Intas Pharmaceuticals Limited; Sandoz Group AG; Apotex Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Fulvestrant Injection Market Characteristics

3. Fulvestrant Injection Market Trends And Strategies

4. Fulvestrant Injection Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Fulvestrant Injection Growth Analysis And Strategic Analysis Framework

• 5.1. Global Fulvestrant Injection PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Fulvestrant Injection Market Growth Rate Analysis
• 5.4. Global Fulvestrant Injection Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Fulvestrant Injection Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Fulvestrant Injection Total Addressable Market (TAM)

6. Fulvestrant Injection Market Segmentation

• 6.1. Global Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Original Drugs
• Generic Drugs
• 6.2. Global Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Dose Vials
• Multi-Dose Vials
• Pre-Filled Syringes
• 6.3. Global Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intramuscular Injection
• Subcutaneous Injection
• Intravenous Injection
• 6.4. Global Fulvestrant Injection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer Treatment
• Hormone Receptor-Positive Metastatic Breast Cancer
• Other Applications
• 6.5. Global Fulvestrant Injection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.6. Global Fulvestrant Injection Market, Sub-Segmentation Of Original Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Branded Formulations
• Patented Molecules
• Hospital-Procured Brands
• Oncologist-Prescribed Brands
• High-Cost Segment
• 6.7. Global Fulvestrant Injection Market, Sub-Segmentation Of Generic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Branded Generics
• Non-Branded Generics
• Biosimilar Generics
• Low-Cost Institutional Generics
• Tender-Based Supply Generics

7. Fulvestrant Injection Market Regional And Country Analysis

• 7.1. Global Fulvestrant Injection Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Fulvestrant Injection Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Fulvestrant Injection Market

• 8.1. Asia-Pacific Fulvestrant Injection Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Fulvestrant Injection Market

• 9.1. China Fulvestrant Injection Market Overview
• 9.2. China Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Fulvestrant Injection Market

• 10.1. India Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Fulvestrant Injection Market

• 11.1. Japan Fulvestrant Injection Market Overview
• 11.2. Japan Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Fulvestrant Injection Market

• 12.1. Australia Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Fulvestrant Injection Market

• 13.1. Indonesia Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Fulvestrant Injection Market

• 14.1. South Korea Fulvestrant Injection Market Overview
• 14.2. South Korea Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Fulvestrant Injection Market

• 15.1. Western Europe Fulvestrant Injection Market Overview
• 15.2. Western Europe Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Fulvestrant Injection Market

• 16.1. UK Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Fulvestrant Injection Market

• 17.1. Germany Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Fulvestrant Injection Market

• 18.1. France Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Fulvestrant Injection Market

• 19.1. Italy Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Fulvestrant Injection Market

• 20.1. Spain Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Fulvestrant Injection Market

• 21.1. Eastern Europe Fulvestrant Injection Market Overview
• 21.2. Eastern Europe Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Fulvestrant Injection Market

• 22.1. Russia Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Fulvestrant Injection Market

• 23.1. North America Fulvestrant Injection Market Overview
• 23.2. North America Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Fulvestrant Injection Market

• 24.1. USA Fulvestrant Injection Market Overview
• 24.2. USA Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Fulvestrant Injection Market

• 25.1. Canada Fulvestrant Injection Market Overview
• 25.2. Canada Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Fulvestrant Injection Market

• 26.1. South America Fulvestrant Injection Market Overview
• 26.2. South America Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Fulvestrant Injection Market

• 27.1. Brazil Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Fulvestrant Injection Market

• 28.1. Middle East Fulvestrant Injection Market Overview
• 28.2. Middle East Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Fulvestrant Injection Market

• 29.1. Africa Fulvestrant Injection Market Overview
• 29.2. Africa Fulvestrant Injection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Fulvestrant Injection Market, Segmentation By Dosage Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Fulvestrant Injection Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Fulvestrant Injection Market Competitive Landscape And Company Profiles

• 30.1. Fulvestrant Injection Market Competitive Landscape
• 30.2. Fulvestrant Injection Market Company Profiles
  • 30.2.1. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Intas Pharmaceuticals Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sandoz Group AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Apotex Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Fulvestrant Injection Market Other Major And Innovative Companies

• 31.1. Dr. Reddy's Laboratories
• 31.2. Cadila Pharmaceuticals Ltd.
• 31.3. Amneal Pharmaceuticals Inc.
• 31.4. Biocon Ltd.
• 31.5. Glenmark Pharmaceuticals Ltd.
• 31.6. Alkem Laboratories Ltd.
• 31.7. Alembic Pharmaceuticals
• 31.8. Eskayef Pharmaceuticals Ltd.
• 31.9. Natco Pharma Ltd.
• 31.10. Celon Laboratories Ltd.
• 31.11. Therdose Pharma
• 31.12. Eugia Pharma
• 31.13. Formative Pharma
• 31.14. Halsted Pharma
• 31.15. Metta Life Sciences

32. Global Fulvestrant Injection Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fulvestrant Injection Market

34. Recent Developments In The Fulvestrant Injection Market

35. Fulvestrant Injection Market High Potential Countries, Segments and Strategies

• 35.1 Fulvestrant Injection Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Fulvestrant Injection Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Fulvestrant Injection Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer